• Twist Bioscience guided FY2026 revenue of $442-$447 million, following FY2025 revenue of about $377 million.
• Targeted adjusted EBITDA breakeven in Q4 FY2026, supported by gross margin above 50% guidance for FY2026.
• Reported about 60% cost reduction, about 70% waste reduction, about 73% turnaround-time reduction since 1H2023, driving about 4x capacity gains.
• Highlighted 2Q FY2026 revenue mix: therapeutics $40.8 million, diagnostics $40 million, global supply partners $11.4 million; supply partners about 75% tied to NGS.
• Outlined automation plans to lift integrated systems to 26 by 2027 from 12 in 2024, aiming to scale output with less space.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.